Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

The Effect of Vitamin D treatment on COVID 19- Patients, an Inverted Propensity Score Weighting (IPSW), and Inverted Probability of Treatment Weighting (IPTW) Analyzed Study

Wadi Al Ramahi et al., The International Arabic Journal of Antimicrobial Agents, doi:10.3823/862
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Retrospective study comparing 847 patients receiving ≤149,000IU vitamin D and 170 receiving ≥150,000IU, showing no significant differences, however the result may not be very meaningful - membership in the higher cumulative dose group requires longer hospitalization, e.g., patients discharged shortly after admission (a positive outcome) could not be in the higher cumulative dose group.
Wadi Al Ramahi et al., 7 Mar 2022, peer-reviewed, 15 authors.
This PaperVitamin DAll
The Effect of Vitamin D treatment on COVID 19- Patients, an Inverted Propensity Score Weighting (IPSW), and Inverted Probability of Treatment Weighting (IPTW) Analyzed Study
Jamal Wadi Al Ramahi, Nour Hasan, Amal Matar, Ma'en Maher Al-Ali, Lara Abdulhadi, Dania Abu Kaf, Waseem Saadeh, Nour Hamdan, Hassan Abukhalaf, Mohamed Gharaibeh, Hanadi Hamadallah, Ala'a Bader, Mohammad Atout, Sae’ed Moh. Mar’i, Tamer Alhamed
The International Arabic Journal of Antimicrobial Agents, doi:10.3823/862
Background: Vitamin D3 (1,25(OH) 2 cholecalciferol) as a treatment for COVID 19 patients is being disputed, and a clear clinical benefit is not being confirmed. Methods: A retrospective evaluation for COVID-19 patients who were treated with various cumulative doses of vitamin D. Data was extracted from the COVID-19 database, it included patients admitted to three hospitals in Amman, Jordan. Characteristics of patients were tabulated and compared for all-cohort, and propensity score index (PSI) adjustment. The comparison was based on two vitamin D strata (≤ 149,000 i.u. and > 150,000 i.u.). Logistic regression analysis was utilized to predict recovery, the need for oxygen, and all-cause mortality for all-cohort, IPSW, and IPTW patients, based on vitamin D cumulative doses during their hospital stay. Results: 1131 all-cohort and 768 PSI-adjusted patients were recruited. Except for antibiotics and antivirals, all other characteristics were balanced (P = NS). There were 1017 patients on vitamin D, 847 received cumulative ≤ 149,000 i.u., and 170 patients received cumulative dose
The Journal is an open access peer-reviewed journal that publishes scientific papers about all aspects of antimicrobials. The journal will publish original research articles, reviews, brief reports and case reports dealing with basic and clinical antibacterial agents, antiviral, antiprotozoals, antituberculuous, antifungal and antihelminthes agents. All manuscripts must be prepared in English, and are subject to a rigorous and fair peer-review process. Accepted papers will immediately appear online. The journal aims to advance the knowledge, attitude and the research of chemotherapy in the Arabic world in cooperation with international, national scientific and public societies as well as research centers with similar aims and objectives.
References
Alanagreh, Alzoughool, Atoum, The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms, Pathogens
Annweiler, Hanotte, De L'eprevier, Sabatier, Lafaie et al., Vitamin D and survival in COVID-19 patients: a quasi-experimental study, The Journal of Steroid Biochemistry and Molecular Biology
Balcells, Rojas, Corre, Martínez-Valdebenito, Ceballos et al., Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial, PLoS Medicine
Castillo, Costa, Barrios, Díaz, Miranda et al., Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study, The Journal of Steroid Biochemistry and Molecular Biology
Dubnov-Raz, Hemilä, Cohen, Rinat, Choleva et al., Vitamin D supplementation and upper respiratory tract infections in adolescent swimmers: a randomized controlled trial, Pediatric Exercise Science
Faqihi, Alharthy, Alodat, Asad, Aletreby et al., A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol, Trials
Kaufman, Niles, Kroll, Bi, Holick, SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, PloS One
Marik, Kory, Varon, Iglesias, Meduri, MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale, Expert Review of Anti-infective Therapy
Nittari, Pallotta, Amenta, Tayebati, Current pharmacological treatments for SARS-COV-2: A narrative review, European Journal of Pharmacology
Panfili, Roversi, Rossi, Cappa, Fintini, Possible role of vitamin D in Covid-19 infection in pediatric population, Journal of Endocrinological Investigation
Science, Maguire, Russell, Smieja, Walter et al., Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents, Clinical Infectious Diseases
Sundaram, Coleman, Vitamin D and influenza, Advances in Nutrition
Thomas, Patel, Bittel, Wolski, Wang et al., Effect of highdose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial, JAMA Network Open
Urashima, Takaakisegawa, Okazaki, Kurihara, Wada et al., Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren, The American Journal of Clinical Nutrition
Wong, Lam, Fong, Leung, Chin et al., Frequency and distribution of chest radiographic findings in patients positive for COVID-19, Radiology
{ 'indexed': {'date-parts': [[2022, 3, 29]], 'date-time': '2022-03-29T02:59:36Z', 'timestamp': 1648522776515}, 'reference-count': 0, 'publisher': 'International Medical Publisher (Fundacion de Neurociencias)', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 3, 7]], 'date-time': '2022-03-07T00:00:00Z', 'timestamp': 1646611200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['int. arab. j antimicrob. agents'], 'abstract': '<jats:p>Background\n' 'Vitamin D3 (1,25(OH)2 cholecalciferol) as a treatment for COVID 19 patients is being ' 'disputed, and a clear clinical benefit is not being confirmed.\n' 'Methods\n' 'A retrospective evaluation for COVID-19 patients who were treated with various cumulative ' 'doses of vitamin D. Data was extracted from the COVID-19 database, it included patients ' 'admitted to three hospitals in Amman, Jordan. Characteristics of patients were tabulated and ' 'compared for all-cohort, and propensity score index (PSI) adjustment, The comparison was ' 'based on two vitamin D strata ((≤ 149,000 i.u. and &gt; 150,000 i.u.). Logistic regression ' 'analysis was utilized to predict recovery, the need for oxygen, and all-cause mortality for ' 'all-cohort, IPSW, and IPTW patients, based on vitamin D cumulative doses during their ' 'hospital stay.\n' 'Results\n' '\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 1131 all-cohort and 768 PSI-adjusted patients ' 'were recruited. Except for antibiotics and antivirals, all other characteristics were ' 'balanced (P = NS). There were 1017 patients on vitamin D, 847 received cumulative ≤ 149,000 ' 'i.u., and 170 patients received cumulative dose ≥ 150,000 i.u. (Range 1000 – 385000). It was ' 'demonstrated that escalating cumulative doses of vitamin D did not contribute to the assessed ' 'outcomes; all-cohort patients (OR = 1.000, 95% C.I. 1.000 to 1.000), IPSW (OR = 1.000, 95% ' 'C.I. 1.000 to 1.000), and the IPTW (OR = 1.000, 95% C.I. 1.000 to 1.000).\n' 'Conclusion\n' '\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 In our patients’ cohorts, we could not ' 'demonstrate a beneficial effect for vitamin D therapy in COVID-19 patients for recovery, the ' 'need for home oxygen, and all-cause mortality, by hospital discharge.</jats:p>', 'DOI': '10.3823/862', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 7]], 'date-time': '2022-03-07T18:27:04Z', 'timestamp': 1646677624000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'The Effect of Vitamin D treatment on COVID 19- Patients, an Inverted Propensity Score ' 'Weighting (IPSW), and Inverted Probability of Treatment Weighting (IPTW) Analyzed Study'], 'prefix': '10.3823', 'volume': '12', 'author': [ {'given': 'Jamal', 'family': 'Wadi Al Ramahi', 'sequence': 'first', 'affiliation': []}, {'given': 'Nour', 'family': 'Hasan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amal', 'family': 'Matar', 'sequence': 'additional', 'affiliation': []}, {'given': "Ma'en", 'family': 'Maher Al-Ali', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lara', 'family': 'Abdulhadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dania', 'family': 'Abu Kaf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Waseem', 'family': 'Saadeh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nour', 'family': 'Hamdan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hassan', 'family': 'AbuKhalaf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohamed', 'family': 'Gharaibeh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hanadi', 'family': 'Hamadallah', 'sequence': 'additional', 'affiliation': []}, {'given': "Ala'a", 'family': 'Bader', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad', 'family': 'Atout', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sae’ed', 'family': 'Moh. Mar’I', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tamer', 'family': 'Alhamed', 'sequence': 'additional', 'affiliation': []}], 'member': '2155', 'published-online': {'date-parts': [[2022, 3, 7]]}, 'container-title': ['The International Arabic Journal of Antimicrobial Agents'], 'original-title': [], 'link': [ { 'URL': 'http://imed.pub/ojs/index.php/IAJAA/article/download/2391/2120', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://imed.pub/ojs/index.php/IAJAA/article/download/2391/2120', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 7]], 'date-time': '2022-03-07T18:27:05Z', 'timestamp': 1646677625000}, 'score': 1, 'resource': {'primary': {'URL': 'http://imed.pub/ojs/index.php/IAJAA/article/view/2391'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 7]]}, 'references-count': 0, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 1, 1]]}}, 'URL': 'http://dx.doi.org/10.3823/862', 'relation': {}, 'ISSN': ['2174-9094'], 'issn-type': [{'value': '2174-9094', 'type': 'electronic'}], 'subject': ['Pharmacology (medical)', 'Microbiology (medical)', 'Pharmacology'], 'published': {'date-parts': [[2022, 3, 7]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit